OpenArc Corporate Advisory’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
OpenArc Corporate Advisory's REGN Position: Q2 2026 in Review
OpenArc Corporate Advisory reduced its Regeneron Pharmaceuticals (REGN) stake by 15% in Q2 2026, selling an estimated $82.4K and leaving 688 shares worth $429K. The position accounts for 0.01% of the portfolio, ranked #529.
OpenArc Corporate Advisory first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $625K in Q1 2026. 1,330 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- OpenArc Corporate Advisory held 688 shares of Regeneron Pharmaceuticals worth $429K as of Q2 2026.
- OpenArc Corporate Advisory sold 121 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $82.4K.
- Regeneron Pharmaceuticals made up 0.01% of OpenArc Corporate Advisory's portfolio in Q2 2026, its #529 holding.
- OpenArc Corporate Advisory first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
- OpenArc Corporate Advisory's Regeneron Pharmaceuticals position peaked at $625K in Q1 2026.
- 1,330 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on OpenArc Corporate Advisory's 13F filing for Q2 2026, filed 5 Aug 2026.